Operating Income (Loss) of Lexaria Bioscience Corp. from 31 Jul 2013 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Lexaria Bioscience Corp. quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Jul 2013 to 30 Nov 2025.
  • Lexaria Bioscience Corp. Operating Income (Loss) for the quarter ending 30 Nov 2025 was $1,573,631, a 42% increase year-over-year.
  • Lexaria Bioscience Corp. Operating Income (Loss) for the twelve months ending 30 Nov 2025 was $10,763,661, a 47% decline year-over-year.
  • Lexaria Bioscience Corp. annual Operating Income (Loss) for 2025 was $11,880,737, a 107% decline from 2024.
  • Lexaria Bioscience Corp. annual Operating Income (Loss) for 2024 was $5,753,130, a 12% increase from 2023.
  • Lexaria Bioscience Corp. annual Operating Income (Loss) for 2023 was $6,534,022, a 1.3% increase from 2022.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Lexaria Bioscience Corp. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $10,763,661 $1,573,631 +$1,117,076 +42% 01 Sep 2025 30 Nov 2025 10-Q 13 Jan 2026 2026 Q1
Q3 2025 $11,880,737 $2,688,597 -$485,533 -22% 01 Jun 2025 31 Aug 2025 10-K 28 Nov 2025 2025 FY
Q2 2025 $11,395,204 $3,750,421 -$2,007,502 -115% 01 Mar 2025 31 May 2025 10-Q 14 Jul 2025 2025 Q3
Q1 2025 $9,387,702 $2,751,012 -$2,083,007 -312% 01 Dec 2024 28 Feb 2025 10-Q 14 Apr 2025 2025 Q2
Q4 2024 $7,304,695 $2,690,707 -$1,551,565 -136% 01 Sep 2024 30 Nov 2024 10-Q 13 Jan 2026 2026 Q1
Q3 2024 $5,753,130 $2,203,064 -$1,088,951 -98% 01 Jun 2024 31 Aug 2024 10-K 28 Nov 2025 2025 FY
Q2 2024 $4,664,179 $1,742,919 +$657,946 +27% 01 Mar 2024 31 May 2024 10-Q 14 Jul 2025 2025 Q3
Q1 2024 $5,322,125 $668,005 +$655,620 +50% 01 Dec 2023 29 Feb 2024 10-Q 14 Apr 2025 2025 Q2
Q4 2023 $5,977,745 $1,139,142 +$556,277 +33% 01 Sep 2023 30 Nov 2023 10-Q 10 Jan 2025 2025 Q1
Q3 2023 $6,534,022 $1,114,113 01 Jun 2023 31 Aug 2023 10-K 26 Nov 2024 2024 FY
Q2 2023 $2,400,865 +$17,473 +0.72% 01 Mar 2023 31 May 2023 10-Q 12 Jul 2024 2024 Q3
Q1 2023 $1,323,625 01 Dec 2022 28 Feb 2023 10-Q 09 Apr 2024 2024 Q2
Q4 2022 $1,695,419 01 Sep 2022 30 Nov 2022 10-Q 12 Jan 2024 2023 Q1
Q2 2022 $2,418,338 +$148,214 +5.8% 01 Mar 2022 31 May 2022 10-Q 14 Jul 2022 2022 Q3
Q2 2021 $2,566,552 01 Mar 2021 31 May 2021 10-Q 14 Jul 2022 2022 Q3
Q4 2017 $578,713 -$178,160 -44% 01 Sep 2017 30 Nov 2017 10-Q 12 Jan 2018 2018 Q1
Q4 2016 $1,266,060 $400,553 +$11,189 +2.7% 01 Sep 2016 30 Nov 2016 10-Q 12 Jan 2018 2018 Q1
Q3 2016 $1,277,249 $326,749 +$288,832 +47% 01 Jun 2016 31 Aug 2016 10-K 29 Nov 2016 2016 FY
Q2 2016 $1,566,081 $264,201 +$246,807 +48% 01 Mar 2016 31 May 2016 10-Q 13 Jul 2016 2016 Q3
Q1 2016 $1,812,888 $274,557 +$184,051 +40% 01 Dec 2015 29 Feb 2016 10-Q 13 Apr 2016 2016 Q2
Q4 2015 $1,996,939 $411,742 -$13,669 -3.4% 01 Sep 2015 30 Nov 2015 10-Q 08 Jan 2016 2016 Q1
Q3 2015 $1,983,270 $615,581 01 Jun 2015 31 Aug 2015 10-K 29 Nov 2016 2016 FY
Q2 2015 $511,008 +$56,946 +10% 01 Mar 2015 31 May 2015 10-Q 13 Jul 2016 2016 Q3
Q1 2015 $458,608 29 Nov 2014 28 Feb 2015 10-Q 13 Apr 2016 2016 Q2
Q4 2014 $398,073 01 Sep 2014 30 Nov 2014 10-Q 08 Jan 2016 2016 Q1
Q2 2014 $567,954 -$510,285 -885% 01 May 2014 31 Jul 2014 10-Q 14 Nov 2014 2014 Q3
Q2 2013 $57,669 01 May 2013 31 Jul 2013 10-Q 14 Nov 2014 2014 Q3

Lexaria Bioscience Corp. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $11,880,737 -$6,127,607 -107% 01 Sep 2024 31 Aug 2025 10-K 28 Nov 2025 2025 FY
2024 $5,753,130 +$780,892 +12% 01 Sep 2023 31 Aug 2024 10-K 28 Nov 2025 2025 FY
2023 $6,534,022 +$85,017 +1.3% 01 Sep 2022 31 Aug 2023 10-K 26 Nov 2024 2024 FY
2022 $6,619,039 -$932,187 -16% 01 Sep 2021 31 Aug 2022 10-K 20 Nov 2023 2023 FY
2021 $5,686,852 01 Sep 2020 31 Aug 2021 10-K 28 Nov 2022 2022 FY
2016 $1,277,249 +$706,021 +36% 01 Sep 2015 31 Aug 2016 10-K 29 Nov 2016 2016 FY
2015 $1,983,270 -$423,929 -27% 01 Sep 2014 31 Aug 2015 10-K 29 Nov 2016 2016 FY
2014 $1,559,341 01 Sep 2013 31 Aug 2014 10-K 27 Nov 2015 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.